GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » Capex-to-Operating-Cash-Flow

Deep Medicine Acquisition (Deep Medicine Acquisition) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Deep Medicine Acquisition's Capital Expenditure for the three months ended in Sep. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2023 was $-0.27 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Deep Medicine Acquisition Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Deep Medicine Acquisition's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deep Medicine Acquisition Capex-to-Operating-Cash-Flow Chart

Deep Medicine Acquisition Annual Data
Trend Mar21 Mar22 Mar23
Capex-to-Operating-Cash-Flow
- - -

Deep Medicine Acquisition Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Deep Medicine Acquisition's Capex-to-Operating-Cash-Flow

For the Shell Companies subindustry, Deep Medicine Acquisition's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deep Medicine Acquisition's Capex-to-Operating-Cash-Flow Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Deep Medicine Acquisition's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Deep Medicine Acquisition's Capex-to-Operating-Cash-Flow falls into.



Deep Medicine Acquisition Capex-to-Operating-Cash-Flow Calculation

Deep Medicine Acquisition's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -1.036
=N/A

Deep Medicine Acquisition's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.269
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Deep Medicine Acquisition  (NAS:DMAQ) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Deep Medicine Acquisition Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
595 Madison Avenue, 12th Floor, New York, NY, USA, 10017
Website
Deep Medicine Acquisition Corp is a blank check company.
Executives
John Chiang director 3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen director, officer: Chief Executive Officer C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo officer: Chief Financial Officer 40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc 10 percent owner 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017

Deep Medicine Acquisition (Deep Medicine Acquisition) Headlines

From GuruFocus

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By Value_Insider Value_Insider 10-24-2022

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By GlobeNewswire GlobeNewswire 10-24-2022